Blood-brain Barrier Drug Discovery for Central Nervous System Infections

2005 ◽  
Vol 5 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Ambrose Jong ◽  
Sheng-He Huang
NeuroRx ◽  
2005 ◽  
Vol 2 (4) ◽  
pp. 554-571 ◽  
Author(s):  
Mohammad S. Alavijeh ◽  
Mansoor Chishty ◽  
M. Zeeshan Qaiser ◽  
Alan M. Palmer

2019 ◽  
Vol 13 ◽  
pp. 117906951985111 ◽  
Author(s):  
Suzanne Jackowski

Multiple approaches to therapy have been proposed for the rare inherited neurodegenerative disease associated with mutations in the PANK2 gene, called pantothenate-kinase-associated neurodegeneration (PKAN). Penetration of the blood-brain barrier for treatment of a central nervous system (CNS) disorder is a major challenge in drug discovery. Evaluation of the biochemistry and medicinal chemistry of the proposed therapies reveals potential liabilities among several compounds under consideration for clinical development.


2021 ◽  
pp. 104952
Author(s):  
Fabien Gosselet ◽  
Rodrigo Azevedo Loiola ◽  
Anna Roig ◽  
Anna Rosell ◽  
Maxime Culot

Physiology ◽  
1998 ◽  
Vol 13 (6) ◽  
pp. 287-293 ◽  
Author(s):  
Gerald A. Grant ◽  
N. Joan Abbott ◽  
Damir Janigro

Endothelial cells exposed to inductive central nervous system factors differentiate into a blood-brain barrier phenotype. The blood-brain barrier frequently obstructs the passage of chemotherapeutics into the brain. Tissue culture systems have been developed to reproduce key properties of the intact blood-brain barrier and to allow for testing of mechanisms of transendothelial drug permeation.


Sign in / Sign up

Export Citation Format

Share Document